Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 7/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16327762 | 0.88 | AGTR2 (0.35) | ACSS2ALOX5AP | |
| SCHEMBL12884191 | 0.88 | CSF1R (0.40) | CSF1RACSS2TP53SMN1; SMN2HTT | |
| SCHEMBL12884199 | 0.86 | CSF1R (0.38) | CSF1RACSS2SMN1; SMN2HTTMAPT | |
| SCHEMBL12884177 | 0.85 | CYP1A2 (0.47) | CSF1RSMN1; SMN2HTTMAPTTNF | |
| SCHEMBL12884204 | 0.84 | CSF1R (0.39) | CSF1RACSS2SMN1; SMN2HTTSTAT3 | |
| SCHEMBL16327722 | 0.76 | ALOX5AP (0.33) | ACSS2MAPTALOX5AP | |
| SCHEMBL16327866 | 0.75 | ALOX5AP (0.38) | ACSS2ALOX5AP | |
| SCHEMBL11984813 | 0.75 | S1PR4 (0.39) | ACSS2ALOX5AP | |
| SCHEMBL12884189 | 0.74 | CSF1R (0.44) | CSF1RACSS2TP53SMN1; SMN2HTT | |
| SCHEMBL8251906 | 0.73 | AGTR2 (0.39) | ACSS2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884215-B2 | 2-substituted benzimidazoles | JANSSEN SCIENCES IRELAND UC (IE) | 2011-02-08 | — | — | US | disclosed |
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | HTR4, HRH4, HTR3C | CSF1R 4057/4885ACSS2 2168/4885TP53 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.